{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:04:17Z","timestamp":1792760657962,"version":"4.5.0"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008131","name":"Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008131","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Platelets are increasingly recognized as important contributors to tumor progression and metastatic dissemination. Platelets facilitate cancer cell survival, their safe transit through the hostile bloodstream, arrest at distant organ sites, and ultimate outgrowth into metastatic lesions. Although multiple platelet-dependent mechanisms have been implicated in cancer progression\u2014including epithelial-mesenchymal transition and the provision of tumor-supportive growth factors\u2014recent studies increasingly highlight immune modulation as a central mechanism underlying platelet-mediated metastasis. Accordingly, this review summarizes current evidence on the molecular and cellular mechanisms by which platelets regulate cytotoxic T lymphocyte and natural killer (NK) cell-mediated anti-tumor immune responses. Special attention is given to platelet-associated immune checkpoint pathways, including the expression and intercellular transfer of Programmed Death-Ligand 1 (PD-L1), as well as to the release of immunomodulatory mediators such as transforming growth factor-\u03b21 (TGF-\u03b21), thromboxane A\u2082 (TXA\u2082), and adenosine generated by platelet ectoenzymes. Finally, the potential implications of platelet-immune interactions for cancer therapy are discussed, with a particular focus on their relevance for immunotherapeutic strategies and metastatic disease control.<\/jats:p>","DOI":"10.1007\/s10555-026-10362-x","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:37:51Z","timestamp":1785897471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Platelets as regulators of anti-tumor immunity: mechanisms and clinical implications"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8942-6136","authenticated-orcid":false,"given":"Martin","family":"Schlesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"issue":"21","key":"10362_CR1","doi-asserted-by":"publisher","first-page":"12772","DOI":"10.3390\/ijms232112772","volume":"23","author":"A Scridon","year":"2022","unstructured":"Scridon, A. (2022). Platelets and their role in hemostasis and thrombosis\u2014from physiology to pathophysiology and therapeutic implications. International Journal of Molecular Sciences, 23(21), 12772. https:\/\/doi.org\/10.3390\/ijms232112772","journal-title":"International Journal of Molecular Sciences"},{"issue":"18","key":"10362_CR2","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1182\/blood-2013-11-462432","volume":"123","author":"CN Morrell","year":"2014","unstructured":"Morrell, C. N., Aggrey, A. A., Chapman, L. M., & Modjeski, K. L. (2014). Emerging roles for platelets as immune and inflammatory cells. Blood, 123(18), 2759\u20132767. https:\/\/doi.org\/10.1182\/blood-2013-11-462432","journal-title":"Blood"},{"issue":"4","key":"10362_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nri2956","volume":"11","author":"JW Semple","year":"2011","unstructured":"Semple, J. W., Italiano, J. E., & Freedman, J. (2011). Platelets and the immune continuum. Nature Reviews. Immunology, 11(4), 264\u2013274. https:\/\/doi.org\/10.1038\/nri2956","journal-title":"Nature Reviews. Immunology"},{"issue":"4","key":"10362_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1055\/s-0037-1615646","volume":"85","author":"RJ Berckmans","year":"2001","unstructured":"Berckmans, R. J., Nieuwland, R., B\u00f6ing, A. N., Romijn, F. P., Hack, C. E., & Sturk, A. (2001). Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thrombosis and Haemostasis, 85(4), 639\u2013646.","journal-title":"Thrombosis and Haemostasis"},{"issue":"23","key":"10362_CR5","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1182\/blood.2019004119","volume":"137","author":"S Lazar","year":"2021","unstructured":"Lazar, S., & Goldfinger, L. E. (2021). Platelets and extracellular vesicles and their cross talk with cancer. Blood, 137(23), 3192\u20133200. https:\/\/doi.org\/10.1182\/blood.2019004119","journal-title":"Blood"},{"issue":"3","key":"10362_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1160\/TH06-06-0313","volume":"97","author":"EI Sinauridze","year":"2007","unstructured":"Sinauridze, E. I., Kireev, D. A., Popenko, N. Y., Pichugin, A. V., Panteleev, M. A., Krymskaya, O. V., & Ataullakhanov, F. I. (2007). Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thrombosis and Haemostasis, 97(3), 425\u2013434.","journal-title":"Thrombosis and Haemostasis"},{"issue":"6","key":"10362_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s11373-006-9107-5","volume":"13","author":"S-C Lo","year":"2006","unstructured":"Lo, S.-C., Hung, C.-Y., Lin, D.-T., Peng, H.-C., & Huang, T.-F. (2006). Involvement of platelet glycoprotein Ib in platelet microparticle mediated neutrophil activation. Journal of Biomedical Science, 13(6), 787\u2013796. https:\/\/doi.org\/10.1007\/s11373-006-9107-5","journal-title":"Journal of Biomedical Science"},{"issue":"38","key":"10362_CR8","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.M704039200","volume":"282","author":"B Salanova","year":"2007","unstructured":"Salanova, B., Choi, M., Rolle, S., Wellner, M., Luft, F. C., & Kettritz, R. (2007). Beta2-integrins and acquired glycoprotein IIb\/IIIa (GPIIb\/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils. The Journal of Biological Chemistry, 282(38), 27960\u201327969. https:\/\/doi.org\/10.1074\/jbc.M704039200","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10362_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood.V95.4.1317.004k30_1317_1323","volume":"95","author":"SB Forlow","year":"2000","unstructured":"Forlow, S. B., McEver, R. P., & Nollert, M. U. (2000). Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood, 95(4), 1317\u20131323.","journal-title":"Blood"},{"key":"10362_CR10","doi-asserted-by":"publisher","unstructured":"Baj-Krzyworzeka, M., Majka, M., Pratico, D., Ratajczak, J., Vilaire, G., Kijowski, J., \u2026 & Ratajczak, M. Z. (2002). Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Experimental Hematology, 30(5), 450\u2013459. https:\/\/doi.org\/10.1016\/s0301-472x(02)00791-9","DOI":"10.1016\/s0301-472x(02)00791-9"},{"key":"10362_CR11","doi-asserted-by":"publisher","unstructured":"Janowska-Wieczorek, A., Majka, M., Kijowski, J., Baj-Krzyworzeka, M., Reca, R., Turner, A. R., \u2026 & Ratajczak, M. Z. (2001). Platelet-derived microparticles bind to hematopoietic stem\/progenitor cells and enhance their engraftment. Blood, 98(10), 3143\u20133149. https:\/\/doi.org\/10.1182\/blood.v98.10.3143","DOI":"10.1182\/blood.v98.10.3143"},{"issue":"10","key":"10362_CR12","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1182\/blood-2007-06-097410","volume":"111","author":"DL Sprague","year":"2008","unstructured":"Sprague, D. L., Elzey, B. D., Crist, S. A., Waldschmidt, T. J., Jensen, R. J., & Ratliff, T. L. (2008). Platelet-mediated modulation of adaptive immunity: Unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood, 111(10), 5028\u20135036. https:\/\/doi.org\/10.1182\/blood-2007-06-097410","journal-title":"Blood"},{"issue":"8","key":"10362_CR13","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/ijc.24016","volume":"124","author":"O Dashevsky","year":"2009","unstructured":"Dashevsky, O., Varon, D., & Brill, A. (2009). Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. International Journal of Cancer, 124(8), 1773\u20131777. https:\/\/doi.org\/10.1002\/ijc.24016","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10362_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/ijc.20657","volume":"113","author":"A Janowska-Wieczorek","year":"2005","unstructured":"Janowska-Wieczorek, A., Wysoczynski, M., Kijowski, J., Marquez-Curtis, L., Machalinski, B., Ratajczak, J., & Ratajczak, M. Z. (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. International Journal of Cancer, 113(5), 752\u2013760. https:\/\/doi.org\/10.1002\/ijc.20657","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10362_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cardiores.2005.04.007","volume":"67","author":"A Brill","year":"2005","unstructured":"Brill, A., Dashevsky, O., Rivo, J., Gozal, Y., & Varon, D. (2005). Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovascular Research, 67(1), 30\u201338. https:\/\/doi.org\/10.1016\/j.cardiores.2005.04.007","journal-title":"Cardiovascular Research"},{"issue":"3","key":"10362_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1365-2141.2003.04773.x","volume":"124","author":"HK Kim","year":"2004","unstructured":"Kim, H. K., Song, K. S., Chung, J.-H., Lee, K. R., & Lee, S.-N. (2004). Platelet microparticles induce angiogenesis in vitro. British Journal of Haematology, 124(3), 376\u2013384. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04773.x","journal-title":"British Journal of Haematology"},{"issue":"Suppl 1","key":"10362_CR17","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.thromres.2012.08.289","volume":"130","author":"D Varon","year":"2012","unstructured":"Varon, D., Hayon, Y., Dashevsky, O., & Shai, E. (2012). Involvement of platelet derived microparticles in tumor metastasis and tissue regeneration. Thrombosis Research, 130(Suppl 1), S98-99. https:\/\/doi.org\/10.1016\/j.thromres.2012.08.289","journal-title":"Thrombosis Research"},{"key":"10362_CR18","doi-asserted-by":"publisher","unstructured":"Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., \u2026 & Heikenwalder, M. (2019). Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer. Nature Medicine, 25(4), 641\u2013655. https:\/\/doi.org\/10.1038\/s41591-019-0379-5","DOI":"10.1038\/s41591-019-0379-5"},{"issue":"5","key":"10362_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle, M., Begum, S., & Hynes, R. O. (2011). Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell, 20(5), 576\u2013590. https:\/\/doi.org\/10.1016\/j.ccr.2011.09.009","journal-title":"Cancer Cell"},{"issue":"30","key":"10362_CR20","doi-asserted-by":"publisher","first-page":"E3053","DOI":"10.1073\/pnas.1411082111","volume":"111","author":"M Labelle","year":"2014","unstructured":"Labelle, M., Begum, S., & Hynes, R. O. (2014). Platelets guide the formation of early metastatic niches. Proceedings of the National Academy of Sciences of the United States of America, 111(30), E3053-3061. https:\/\/doi.org\/10.1073\/pnas.1411082111","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10362_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ccr.2013.05.008","volume":"24","author":"D Schumacher","year":"2013","unstructured":"Schumacher, D., Strilic, B., Sivaraj, K. K., Wettschureck, N., & Offermanns, S. (2013). Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell, 24(1), 130\u2013137. https:\/\/doi.org\/10.1016\/j.ccr.2013.05.008","journal-title":"Cancer Cell"},{"issue":"3","key":"10362_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.tmrv.2010.03.004","volume":"24","author":"L Mazzucco","year":"2010","unstructured":"Mazzucco, L., Borzini, P., & Gope, R. (2010). Platelet-derived factors involved in tissue repair-from signal to function. Transfusion Medicine Reviews, 24(3), 218\u2013234. https:\/\/doi.org\/10.1016\/j.tmrv.2010.03.004","journal-title":"Transfusion Medicine Reviews"},{"issue":"9","key":"10362_CR23","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ijc.29847","volume":"138","author":"N Li","year":"2016","unstructured":"Li, N. (2016). Platelets in cancer metastasis: To help the \u201cvillain\u201d to do evil. International Journal of Cancer, 138(9), 2078\u20132087. https:\/\/doi.org\/10.1002\/ijc.29847","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10362_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews. Cancer, 11(2), 123\u2013134. https:\/\/doi.org\/10.1038\/nrc3004","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"10362_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1073\/pnas.61.1.46","volume":"61","author":"GJ Gasic","year":"1968","unstructured":"Gasic, G. J., Gasic, T. B., & Stewart, C. C. (1968). Antimetastatic effects associated with platelet reduction. Proceedings of the National Academy of Sciences of the United States of America, 61(1), 46\u201352. https:\/\/doi.org\/10.1073\/pnas.61.1.46","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10362_CR26","first-page":"1295","volume":"59","author":"B Nieswandt","year":"1999","unstructured":"Nieswandt, B., Hafner, M., Echtenacher, B., & M\u00e4nnel, D. N. (1999). Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Research, 59(6), 1295\u20131300.","journal-title":"Cancer Research"},{"issue":"19","key":"10362_CR27","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","volume":"69","author":"H-G Kopp","year":"2009","unstructured":"Kopp, H.-G., Placke, T., & Salih, H. R. (2009). Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Research, 69(19), 7775\u20137783. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2123","journal-title":"Cancer Research"},{"issue":"2","key":"10362_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","volume":"72","author":"T Placke","year":"2012","unstructured":"Placke, T., \u00d6rgel, M., Schaller, M., Jung, G., Rammensee, H.-G., Kopp, H.-G., & Salih, H. R. (2012). Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Research, 72(2), 440\u2013448. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1872","journal-title":"Cancer Research"},{"key":"10362_CR29","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang, X., Teng, F., Kong, L., & Yu, J. (2016). PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy, 9, 5023\u20135039. https:\/\/doi.org\/10.2147\/OTT.S105862","journal-title":"OncoTargets and Therapy"},{"issue":"1","key":"10362_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018). Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. Journal for Immunotherapy of Cancer, 6(1), 8. https:\/\/doi.org\/10.1186\/s40425-018-0316-z","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"3","key":"10362_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel, J. J., Chowell, D., & Chan, T. A. (2019). The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews. Cancer, 19(3), 133\u2013150. https:\/\/doi.org\/10.1038\/s41568-019-0116-x","journal-title":"Nature Reviews. Cancer"},{"issue":"4","key":"10362_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022). Immune-checkpoint inhibitors: Long-term implications of toxicity. Nature Reviews. Clinical Oncology, 19(4), 254\u2013267. https:\/\/doi.org\/10.1038\/s41571-022-00600-w","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10362_CR33","doi-asserted-by":"publisher","unstructured":"Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., \u2026 & Hodi, F. S. (2018). Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36(17), 1668\u20131674. https:\/\/doi.org\/10.1200\/JCO.2017.75.6270","DOI":"10.1200\/JCO.2017.75.6270"},{"key":"10362_CR34","doi-asserted-by":"publisher","unstructured":"Rolfes, V., Idel, C., Pries, R., Pl\u00f6tze-Martin, K., Habermann, J., Gemoll, T., \u2026 & Wollenberg, B. (2018). PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget, 9(44), 27460\u201327470. https:\/\/doi.org\/10.18632\/oncotarget.25446","DOI":"10.18632\/oncotarget.25446"},{"issue":"Supplement 1","key":"10362_CR35","doi-asserted-by":"publisher","first-page":"11208","DOI":"10.1182\/blood-2022-170261","volume":"140","author":"AK Hubben","year":"2022","unstructured":"Hubben, A. K., Shim, Y. J., Kundu, S., Cameron, S. J., & McCrae, K. R. (2022). Programmed death ligand 1 is released in platelet-derived extracellular vesicles. Blood, 140(Supplement 1), 11208\u201311209. https:\/\/doi.org\/10.1182\/blood-2022-170261","journal-title":"Blood"},{"key":"10362_CR36","doi-asserted-by":"publisher","unstructured":"Li, Y., Xin, G., Li, S., Dong, Y., Zhu, Y., Yu, X., \u2026 & Huang, W. (2022). PD-L1 regulates platelet activation and thrombosis via Caspase-3\/GSDME pathway. Frontiers in Pharmacology, 13, 921414. https:\/\/doi.org\/10.3389\/fphar.2022.921414","DOI":"10.3389\/fphar.2022.921414"},{"issue":"20","key":"10362_CR37","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1182\/bloodadvances.2021006120","volume":"6","author":"Q Guo","year":"2022","unstructured":"Guo, Q., Malloy, M. W., Roweth, H. G., McAllister, S. S., Italiano, J. E., & Battinelli, E. M. (2022). Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro. Blood Advances, 6(20), 5668\u20135675. https:\/\/doi.org\/10.1182\/bloodadvances.2021006120","journal-title":"Blood Advances"},{"key":"10362_CR38","doi-asserted-by":"publisher","unstructured":"Schneider, M. A., Heeb, L., Beffinger, M. M., Pantelyushin, S., Linecker, M., Roth, L., \u2026 & Clavien, P.-A. (2021). Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Science Translational Medicine, 13(611), eabc8188. https:\/\/doi.org\/10.1126\/scitranslmed.abc8188","DOI":"10.1126\/scitranslmed.abc8188"},{"key":"10362_CR39","doi-asserted-by":"publisher","unstructured":"Hinterleitner, C., Str\u00e4hle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., \u2026 & Zender, L. (2021). Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nature Communications, 12(1), 7005. https:\/\/doi.org\/10.1038\/s41467-021-27303-7","DOI":"10.1038\/s41467-021-27303-7"},{"key":"10362_CR40","doi-asserted-by":"publisher","unstructured":"Colarusso, C., Falanga, A., Terlizzi, M., De Rosa, I., Somma, P., Sommella, E. M., \u2026 & Sorrentino, R. (2023). High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 168, 115709. https:\/\/doi.org\/10.1016\/j.biopha.2023.115709","DOI":"10.1016\/j.biopha.2023.115709"},{"key":"10362_CR41","doi-asserted-by":"publisher","unstructured":"Zaslavsky, A. B., Adams, M. P., Cao, X., Maj, T., Choi, J. E., Stangl-Kremser, J., \u2026 & Palapattu, G. S. (2020). Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. Scientific Reports, 10(1), 19296. https:\/\/doi.org\/10.1038\/s41598-020-76351-4","DOI":"10.1038\/s41598-020-76351-4"},{"key":"10362_CR42","doi-asserted-by":"publisher","unstructured":"Zhou, M., Feng, Y., Zhang, X., Chen, J., Yao, N., Fu, S., \u2026 & Yang, N. (2024). Platelet-derived microparticles adoptively transfer integrin \u03b23 to promote antitumor effect of tumor-infiltrating T cells. Oncoimmunology, 13(1), 2304963. https:\/\/doi.org\/10.1080\/2162402X.2024.2304963","DOI":"10.1080\/2162402X.2024.2304963"},{"key":"10362_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen, X., & Zhao, B. (2018). Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: Meta-analysis. BMJ (Clinical research ed.), 362, Article k3529. https:\/\/doi.org\/10.1136\/bmj.k3529","journal-title":"BMJ (Clinical research ed.)"},{"issue":"1","key":"10362_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10555-016-9652-y","volume":"36","author":"Y Khagi","year":"2017","unstructured":"Khagi, Y., Kurzrock, R., & Patel, S. P. (2017). Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Reviews, 36(1), 179\u2013190. https:\/\/doi.org\/10.1007\/s10555-016-9652-y","journal-title":"Cancer Metastasis Reviews"},{"key":"10362_CR45","doi-asserted-by":"publisher","unstructured":"Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., \u2026 & Ascierto, P. A. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. The New England Journal of Medicine, 372(4), 320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","DOI":"10.1056\/NEJMoa1412082"},{"key":"10362_CR46","doi-asserted-by":"publisher","unstructured":"Schaubaecher, J. B., Smiljanov, B., Haring, F., Steiger, K., Wu, Z., Ugurluoglu, A., \u2026 & Reichel, C. A. (2024). Procoagulant platelets promote immune evasion in triple-negative breast cancer. Blood, 144(2), 216\u2013226. https:\/\/doi.org\/10.1182\/blood.2023022928","DOI":"10.1182\/blood.2023022928"},{"key":"10362_CR47","doi-asserted-by":"publisher","unstructured":"Borg, J. P., Marchetto, S., Le Bivic, A., Ollendorff, V., Jaulin-Bastard, F., Saito, H., \u2026 & Birnbaum, D. (2000). ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2\/HER2 receptor. Nature Cell Biology, 2(7), 407\u2013414. https:\/\/doi.org\/10.1038\/35017038","DOI":"10.1038\/35017038"},{"issue":"47","key":"10362_CR48","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.1038\/s41388-020-01478-7","volume":"39","author":"M-J Santoni","year":"2020","unstructured":"Santoni, M.-J., Kashyap, R., Camoin, L., & Borg, J.-P. (2020). The Scribble family in cancer: Twentieth anniversary. Oncogene, 39(47), 7019\u20137033. https:\/\/doi.org\/10.1038\/s41388-020-01478-7","journal-title":"Oncogene"},{"key":"10362_CR49","doi-asserted-by":"publisher","first-page":"1474798","DOI":"10.3389\/fphar.2024.1474798","volume":"15","author":"T Qiu","year":"2024","unstructured":"Qiu, T., Tan, L., Yan, J., & Luo, Q. (2024). Erbin: An important therapeutic target for blocking tumor metastasis. Frontiers in Pharmacology, 15, 1474798. https:\/\/doi.org\/10.3389\/fphar.2024.1474798","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"10362_CR50","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/febs.15450","volume":"288","author":"H Jang","year":"2021","unstructured":"Jang, H., Stevens, P., Gao, T., & Galperin, E. (2021). The leucine-rich repeat signaling scaffolds Shoc2 and Erbin: Cellular mechanism and role in disease. The FEBS Journal, 288(3), 721\u2013739. https:\/\/doi.org\/10.1111\/febs.15450","journal-title":"The FEBS Journal"},{"key":"10362_CR51","doi-asserted-by":"publisher","unstructured":"Zhang, Z., Xu, X., Zhang, D., Zhao, S., Wang, C., Zhang, G., \u2026 & Li, J. (2024). Targeting Erbin-mitochondria axis in platelets\/megakaryocytes promotes B cell-mediated antitumor immunity. Cell Metabolism, 36(3), 541\u2013556.e9. https:\/\/doi.org\/10.1016\/j.cmet.2023.12.020","DOI":"10.1016\/j.cmet.2023.12.020"},{"issue":"1","key":"10362_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0304-3835(83)90082-4","volume":"21","author":"M Pollard","year":"1983","unstructured":"Pollard, M., Luckert, P. H., & Schmidt, M. A. (1983). The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Letters, 21(1), 57\u201361. https:\/\/doi.org\/10.1016\/0304-3835(83)90082-4","journal-title":"Cancer Letters"},{"key":"10362_CR53","doi-asserted-by":"publisher","unstructured":"Elwood, P. C., Morgan, G., Delon, C., Protty, M., Galante, J., Pickering, J., \u2026 & Morris, D. (2021). Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers. Ecancermedicalscience, 15, 1258. https:\/\/doi.org\/10.3332\/ecancer.2021.1258","DOI":"10.3332\/ecancer.2021.1258"},{"key":"10362_CR54","doi-asserted-by":"publisher","unstructured":"Elwood, P., Morgan, G., Watkins, J., Protty, M., Mason, M., Adams, R., \u2026 & Longley, M. (2024). Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against. British Journal of Cancer, 130(1), 3\u20138. https:\/\/doi.org\/10.1038\/s41416-023-02506-5","DOI":"10.1038\/s41416-023-02506-5"},{"key":"10362_CR55","doi-asserted-by":"publisher","unstructured":"G\u00fcller, U., Hayoz, S., Horber, D., Jochum, W., De Dosso, S., Koeberle, D., \u2026 & Joerger, M. (2025). Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The SAKK 41\/13 - prospective randomized placebo-controlled double-blind trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-4048","DOI":"10.1158\/1078-0432.CCR-24-4048"},{"key":"10362_CR56","doi-asserted-by":"publisher","unstructured":"Martling, A., Lindberg, J., Hed Myrberg, I., Nilbert, M., Mayrhofer, M., Gronberg, H., \u2026 & ALASCCA Trial Study Group. (2025). Low-dose aspirin to reduce recurrence rate in colorectal cancer patients with PI3K pathway alterations: 3-year results from a randomized placebo-controlled trial. Journal of Clinical Oncology, 43(4_suppl), LBA125\u2013LBA125. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.LBA125","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA125"},{"key":"10362_CR57","doi-asserted-by":"publisher","unstructured":"Chia, J. W. K., Segelov, E., Deng, Y., Ho, G. F., Wang, W., Han, S., \u2026 & Toh, H. C. (2025). Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology & Hepatology, 10(3), 198\u2013209. https:\/\/doi.org\/10.1016\/S2468-1253(24)00387-X","DOI":"10.1016\/S2468-1253(24)00387-X"},{"issue":"4","key":"10362_CR58","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/jnci\/djad231","volume":"116","author":"C Skriver","year":"2024","unstructured":"Skriver, C., Maltesen, T., Dehlendorff, C., Skovlund, C. W., Schmidt, M., S\u00f8rensen, H. T., & Friis, S. (2024). Long-term aspirin use and cancer risk: A 20-year cohort study. Journal of the National Cancer Institute, 116(4), 530\u2013538. https:\/\/doi.org\/10.1093\/jnci\/djad231","journal-title":"Journal of the National Cancer Institute"},{"key":"10362_CR59","doi-asserted-by":"publisher","unstructured":"Gamba, C. A., Swetter, S. M., Stefanick, M. L., Kubo, J., Desai, M., Spaunhurst, K. M., \u2026 & Tang, J. Y. (2013). Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women\u2019s Health Initiative. Cancer, 119(8), 1562\u20131569. https:\/\/doi.org\/10.1002\/cncr.27817","DOI":"10.1002\/cncr.27817"},{"issue":"12","key":"10362_CR60","doi-asserted-by":"publisher","first-page":"814","DOI":"10.7326\/M15-2117","volume":"164","author":"J Chubak","year":"2016","unstructured":"Chubak, J., Whitlock, E. P., Williams, S. B., Kamineni, A., Burda, B. U., Buist, D. S. M., & Anderson, M. L. (2016). Aspirin for the prevention of cancer incidence and mortality: Systematic evidence reviews for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 164(12), 814\u2013825. https:\/\/doi.org\/10.7326\/M15-2117","journal-title":"Annals of Internal Medicine"},{"key":"10362_CR61","doi-asserted-by":"publisher","unstructured":"McNeil, J. J., Nelson, M. R., Woods, R. L., Lockery, J. E., Wolfe, R., Reid, C. M., \u2026 & ASPREE Investigator Group. (2018). Effect of aspirin on all-cause mortality in the healthy elderly. The New England Journal of Medicine, 379(16), 1519\u20131528. https:\/\/doi.org\/10.1056\/NEJMoa1803955","DOI":"10.1056\/NEJMoa1803955"},{"issue":"2","key":"10362_CR62","doi-asserted-by":"publisher","first-page":"C176","DOI":"10.1152\/ajpcell.00196.2016","volume":"312","author":"A Mitrugno","year":"2017","unstructured":"Mitrugno, A., Sylman, J. L., Ngo, A. T. P., Pang, J., Sears, R. C., Williams, C. D., & McCarty, O. J. T. (2017). Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC. American Journal of Physiology. Cell Physiology, 312(2), C176\u2013C189. https:\/\/doi.org\/10.1152\/ajpcell.00196.2016","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"10362_CR63","unstructured":"Rucker, D., & Dhamoon, A. S. (2026). Physiology, thromboxane A2. In StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539817\/"},{"key":"10362_CR64","doi-asserted-by":"publisher","unstructured":"Yang, J., Yamashita-Kanemaru, Y., Morris, B. I., Contursi, A., Trajkovski, D., Xu, J., \u2026 & Roychoudhuri, R. (2025). Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity. Nature, 640(8060), 1052\u20131061. https:\/\/doi.org\/10.1038\/s41586-025-08626-7","DOI":"10.1038\/s41586-025-08626-7"},{"key":"10362_CR65","doi-asserted-by":"publisher","unstructured":"Lucotti, S., Cerutti, C., Soyer, M., Gil-Bernab\u00e9, A. M., Gomes, A. L., Allen, P. D., \u2026 & Muschel, R. J. (2019). Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1\/thromboxane A2. The Journal of Clinical Investigation, 129(5), 1845\u20131862. https:\/\/doi.org\/10.1172\/JCI121985","DOI":"10.1172\/JCI121985"},{"issue":"5","key":"10362_CR66","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.4049\/jimmunol.1900594","volume":"203","author":"BP Riesenberg","year":"2019","unstructured":"Riesenberg, B. P., Ansa-Addo, E. A., Gutierrez, J., Timmers, C. D., Liu, B., & Li, Z. (2019). Cutting edge: Targeting thrombocytes to rewire anticancer immunity in the tumor microenvironment and potentiate efficacy of PD-1 blockade. Journal of Immunology (Baltimore, Md.: 1950), 203(5), 1105\u20131110. https:\/\/doi.org\/10.4049\/jimmunol.1900594","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"issue":"4","key":"10362_CR67","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.175.4.1091","volume":"175","author":"S Lederman","year":"1992","unstructured":"Lederman, S., Yellin, M. J., Krichevsky, A., Belko, J., Lee, J. J., & Chess, L. (1992). Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). The Journal of Experimental Medicine, 175(4), 1091\u20131101. https:\/\/doi.org\/10.1084\/jem.175.4.1091","journal-title":"The Journal of Experimental Medicine"},{"issue":"28","key":"10362_CR68","doi-asserted-by":"publisher","first-page":"10717","DOI":"10.1073\/pnas.0601539103","volume":"103","author":"R Lesley","year":"2006","unstructured":"Lesley, R., Kelly, L. M., Xu, Y., & Cyster, J. G. (2006). Naive CD4 T cells constitutively express CD40L and augment autoreactive B cell survival. Proceedings of the National Academy of Sciences of the United States of America, 103(28), 10717\u201310722. https:\/\/doi.org\/10.1073\/pnas.0601539103","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10362_CR69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/pl00000776","volume":"58","author":"U Sch\u00f6nbeck","year":"2001","unstructured":"Sch\u00f6nbeck, U., & Libby, P. (2001). The CD40\/CD154 receptor\/ligand dyad. Cellular and Molecular Life Sciences: CMLS, 58(1), 4\u201343. https:\/\/doi.org\/10.1007\/pl00000776","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"key":"10362_CR70","doi-asserted-by":"publisher","unstructured":"Zirlik, A., Maier, C., Gerdes, N., MacFarlane, L., Soosairajah, J., Bavendiek, U., \u2026 & Peter, K. (2007). CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation, 115(12), 1571\u20131580. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.683201","DOI":"10.1161\/CIRCULATIONAHA.106.683201"},{"issue":"9","key":"10362_CR71","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/01.RES.0000070111.98158.6C","volume":"92","author":"DP Inwald","year":"2003","unstructured":"Inwald, D. P., McDowall, A., Peters, M. J., Callard, R. E., & Klein, N. J. (2003). CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circulation Research, 92(9), 1041\u20131048. https:\/\/doi.org\/10.1161\/01.RES.0000070111.98158.6C","journal-title":"Circulation Research"},{"key":"10362_CR72","doi-asserted-by":"publisher","unstructured":"Langer, F., Ingersoll, S. B., Amirkhosravi, A., Meyer, T., Siddiqui, F. A., Ahmad, S., \u2026 & Francis, J. L. (2005). The role of CD40 in CD40L- and antibody-mediated platelet activation. Thrombosis and Haemostasis, 93(6), 1137\u20131146. https:\/\/doi.org\/10.1160\/TH04-12-0774","DOI":"10.1160\/TH04-12-0774"},{"issue":"4","key":"10362_CR73","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1111\/1346-8138.15786","volume":"48","author":"A Kasuya","year":"2021","unstructured":"Kasuya, A., Tokura, Y., & Honda, T. (2021). CD40L from platelet, endothelial cell, and smooth muscle cell may contribute to the proliferation of tumor cell in intravascular large B cell lymphoma. The Journal of Dermatology, 48(4), e180\u2013e181. https:\/\/doi.org\/10.1111\/1346-8138.15786","journal-title":"The Journal of Dermatology"},{"issue":"5\u20136","key":"10362_CR74","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3109\/10428199709055580","volume":"24","author":"HJ Gruss","year":"1997","unstructured":"Gruss, H. J., Herrmann, F., Gattei, V., Gloghini, A., Pinto, A., & Carbone, A. (1997). CD40\/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leukemia & Lymphoma, 24(5\u20136), 393\u2013422. https:\/\/doi.org\/10.3109\/10428199709055580","journal-title":"Leukemia & Lymphoma"},{"key":"10362_CR75","doi-asserted-by":"publisher","unstructured":"Ma, C., Fu, Q., Diggs, L. P., McVey, J. C., McCallen, J., Wabitsch, S., \u2026 & Greten, T. F. (2022). Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer Cell, 40(9), 986\u2013998.e5. https:\/\/doi.org\/10.1016\/j.ccell.2022.08.004","DOI":"10.1016\/j.ccell.2022.08.004"},{"issue":"9","key":"10362_CR76","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41423-023-01036-7","volume":"20","author":"J Wang","year":"2023","unstructured":"Wang, J., Zhao, X., & Wan, Y. Y. (2023). Intricacies of TGF-\u03b2 signaling in Treg and Th17 cell biology. Cellular & Molecular Immunology, 20(9), 1002\u20131022. https:\/\/doi.org\/10.1038\/s41423-023-01036-7","journal-title":"Cellular & Molecular Immunology"},{"issue":"1","key":"10362_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024). TGF-\u03b2 signaling in health, disease, and therapeutics. Signal Transduction and Targeted Therapy, 9(1), Article 61. https:\/\/doi.org\/10.1038\/s41392-024-01764-w","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10362_CR78","doi-asserted-by":"publisher","unstructured":"Derynck, R., Jarrett, J. A., Chen, E. Y., Eaton, D. H., Bell, J. R., Assoian, R. K., \u2026 & Goeddel, D. V. (1985). Human transforming growth factor-\u03b2 complementary DNA sequence and expression in normal and transformed cells. Nature, 316(6030), 701\u2013705. https:\/\/doi.org\/10.1038\/316701a0","DOI":"10.1038\/316701a0"},{"issue":"9","key":"10362_CR79","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1073\/pnas.78.9.5339","volume":"78","author":"AB Roberts","year":"1981","unstructured":"Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981). New class of transforming growth factors potentiated by epidermal growth factor: Isolation from non-neoplastic tissues. Proceedings of the National Academy of Sciences of the United States of America, 78(9), 5339\u20135343. https:\/\/doi.org\/10.1073\/pnas.78.9.5339","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"17","key":"10362_CR80","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1073\/pnas.79.17.5312","volume":"79","author":"CB Childs","year":"1982","unstructured":"Childs, C. B., Proper, J. A., Tucker, R. F., & Moses, H. L. (1982). Serum contains a platelet-derived transforming growth factor. Proceedings of the National Academy of Sciences of the United States of America, 79(17), 5312\u20135316. https:\/\/doi.org\/10.1073\/pnas.79.17.5312","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10362_CR81","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nrc3603","volume":"13","author":"M Pickup","year":"2013","unstructured":"Pickup, M., Novitskiy, S., & Moses, H. L. (2013). The roles of TGF\u03b2 in the tumour microenvironment. Nature Reviews. Cancer, 13(11), 788\u2013799. https:\/\/doi.org\/10.1038\/nrc3603","journal-title":"Nature Reviews. Cancer"},{"issue":"7351","key":"10362_CR82","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature10152","volume":"474","author":"M Shi","year":"2011","unstructured":"Shi, M., Zhu, J., Wang, R., Chen, X., Mi, L., Walz, T., & Springer, T. A. (2011). Latent TGF-\u03b2 structure and activation. Nature, 474(7351), 343\u2013349. https:\/\/doi.org\/10.1038\/nature10152","journal-title":"Nature"},{"issue":"10","key":"10362_CR83","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1128\/mcb.8.10.4162-4168.1988","volume":"8","author":"LE Gentry","year":"1988","unstructured":"Gentry, L. E., Lioubin, M. N., Purchio, A. F., & Marquardt, H. (1988). Molecular events in the processing of recombinant type 1 pre-pro-transforming growth factor beta to the mature polypeptide. Molecular and Cellular Biology, 8(10), 4162\u20134168. https:\/\/doi.org\/10.1128\/mcb.8.10.4162-4168.1988","journal-title":"Molecular and Cellular Biology"},{"issue":"6","key":"10362_CR84","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1091\/mbc.E11-12-1018","volume":"23","author":"R Wang","year":"2012","unstructured":"Wang, R., Zhu, J., Dong, X., Shi, M., Lu, C., & Springer, T. A. (2012). GARP regulates the bioavailability and activation of TGF\u03b2. Molecular Biology of the Cell, 23(6), 1129\u20131139. https:\/\/doi.org\/10.1091\/mbc.E11-12-1018","journal-title":"Molecular Biology of the Cell"},{"key":"10362_CR85","doi-asserted-by":"publisher","unstructured":"Elzey, B. D., Tian, J., Jensen, R. J., Swanson, A. K., Lees, J. R., Lentz, S. R., \u2026 & Ratliff, T. L. (2003). Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity, 19(1), 9\u201319. https:\/\/doi.org\/10.1016\/s1074-7613(03)00177-8","DOI":"10.1016\/s1074-7613(03)00177-8"},{"issue":"1","key":"10362_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2005.12.005","volume":"238","author":"BD Elzey","year":"2005","unstructured":"Elzey, B. D., Sprague, D. L., & Ratliff, T. L. (2005). The emerging role of platelets in adaptive immunity. Cellular Immunology, 238(1), 1\u20139. https:\/\/doi.org\/10.1016\/j.cellimm.2005.12.005","journal-title":"Cellular Immunology"},{"key":"10362_CR87","doi-asserted-by":"publisher","unstructured":"Donatelli, S. S., Zhou, J.-M., Gilvary, D. L., Eksioglu, E. A., Chen, X., Cress, W. D., \u2026 & Djeu, J. Y. (2014). TGF-\u03b2-inducible microRNA-183 silences tumor-associated natural killer cells. Proceedings of the National Academy of Sciences of the United States of America, 111(11), 4203\u20134208. https:\/\/doi.org\/10.1073\/pnas.1319269111","DOI":"10.1073\/pnas.1319269111"},{"key":"10362_CR88","doi-asserted-by":"publisher","unstructured":"Haribhai, D., Luo, X., Chen, J., Jia, S., Shi, L., Schroeder, J. A., \u2026 & Shi, Q. (2016). TGF-\u03b21 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice. Blood Advances, 1(2), 139\u2013151. https:\/\/doi.org\/10.1182\/bloodadvances.2016001453","DOI":"10.1182\/bloodadvances.2016001453"},{"key":"10362_CR89","doi-asserted-by":"publisher","unstructured":"Rachidi, S., Metelli, A., Riesenberg, B., Wu, B. X., Nelson, M. H., Wallace, C., \u2026 & Li, Z. (2017). Platelets subvert T cell immunity against cancer via GARP-TGF\u03b2 axis. Science Immunology, 2(11), eaai7911. https:\/\/doi.org\/10.1126\/sciimmunol.aai7911","DOI":"10.1126\/sciimmunol.aai7911"},{"key":"10362_CR90","doi-asserted-by":"publisher","unstructured":"Metelli, A., Wu, B. X., Riesenberg, B., Guglietta, S., Huck, J. D., Mills, C., \u2026 & Li, Z. (2020). Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2. Science Translational Medicine, 12(525), eaay4860. https:\/\/doi.org\/10.1126\/scitranslmed.aay4860","DOI":"10.1126\/scitranslmed.aay4860"},{"issue":"12","key":"10362_CR91","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1080\/15384047.2015.1078025","volume":"16","author":"ET Alexander","year":"2015","unstructured":"Alexander, E. T., Minton, A. R., Hayes, C. S., Goss, A., Van Ryn, J., & Gilmour, S. K. (2015). Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis. Cancer Biology & Therapy, 16(12), 1802\u20131811. https:\/\/doi.org\/10.1080\/15384047.2015.1078025","journal-title":"Cancer Biology & Therapy"},{"issue":"3","key":"10362_CR92","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich, D. I., & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews. Immunology, 9(3), 162\u2013174. https:\/\/doi.org\/10.1038\/nri2506","journal-title":"Nature Reviews. Immunology"},{"issue":"1","key":"10362_CR93","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4049\/jimmunol.176.1.284","volume":"176","author":"SK Bunt","year":"2006","unstructured":"Bunt, S. K., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2006). Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. Journal of Immunology (Baltimore, Md.\u202f: 1950), 176(1), 284\u2013290. https:\/\/doi.org\/10.4049\/jimmunol.176.1.284","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"key":"10362_CR94","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","volume":"201","author":"FV Suurs","year":"2019","unstructured":"Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A. (2019). A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacology & Therapeutics, 201, 103\u2013119. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.04.006","journal-title":"Pharmacology & Therapeutics"},{"key":"10362_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363102","volume":"15","author":"A Dabkowska","year":"2024","unstructured":"Dabkowska, A., Domka, K., & Firczuk, M. (2024). Advancements in cancer immunotherapies targeting CD20: From pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells. Frontiers in Immunology, 15, Article 1363102. https:\/\/doi.org\/10.3389\/fimmu.2024.1363102","journal-title":"Frontiers in Immunology"},{"issue":"21","key":"10362_CR96","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.3390\/jcm12216737","volume":"12","author":"S Balendran","year":"2023","unstructured":"Balendran, S., Tam, C., & Ku, M. (2023). T-cell engaging antibodies in diffuse large B cell lymphoma-an update. Journal of Clinical Medicine, 12(21), 6737. https:\/\/doi.org\/10.3390\/jcm12216737","journal-title":"Journal of Clinical Medicine"},{"key":"10362_CR97","doi-asserted-by":"publisher","unstructured":"Brouwer-Visser, J., Fiaschi, N., Deering, R. P., Dhanik, A., Cygan, K. J., Zhang, W., \u2026 & Jankovic, V. (2020). Baseline biomarkers of t-cell function correlate with clinical responses to odronextamab (REGN1979), and loss of CD20 target antigen expression identified as a mechanism of treatment resistance. Blood, 136, 10\u201311. https:\/\/doi.org\/10.1182\/blood-2020-137499","DOI":"10.1182\/blood-2020-137499"},{"key":"10362_CR98","doi-asserted-by":"publisher","unstructured":"Lutz, M. S., Klimovich, B., Maurer, S., Heitmann, J. S., M\u00e4rklin, M., Zekri, L., \u2026 & Hinterleitner, C. (2022). Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies. Journal for Immunotherapy of Cancer, 10(2), e003655. https:\/\/doi.org\/10.1136\/jitc-2021-003655","DOI":"10.1136\/jitc-2021-003655"},{"key":"10362_CR99","doi-asserted-by":"publisher","unstructured":"Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., \u2026 & Ravichandran, K. S. (2009). Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature, 461(7261), 282\u2013286. https:\/\/doi.org\/10.1038\/nature08296","DOI":"10.1038\/nature08296"},{"issue":"3","key":"10362_CR100","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/pharmrev.121.000528","volume":"74","author":"GG Yegutkin","year":"2022","unstructured":"Yegutkin, G. G., & Boison, D. (2022). ATP and adenosine metabolism in cancer: Exploitation for therapeutic gain. Pharmacological Reviews, 74(3), 797\u2013822. https:\/\/doi.org\/10.1124\/pharmrev.121.000528","journal-title":"Pharmacological Reviews"},{"key":"10362_CR101","doi-asserted-by":"publisher","unstructured":"Yang, Y., Zhu, L., Xu, Y., Liang, L., Liu, L., Chen, X., \u2026 & Liu, H. (2025). The progress and prospects of targeting the adenosine pathway in cancer immunotherapy. Biomarker Research, 13(1), 75. https:\/\/doi.org\/10.1186\/s40364-025-00784-0","DOI":"10.1186\/s40364-025-00784-0"},{"key":"10362_CR102","doi-asserted-by":"publisher","unstructured":"Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., \u2026 & Wong, C. C.-L. (2017). Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2\/CD39L1 in hepatocellular carcinoma. Nature Communications, 8(1), 517. https:\/\/doi.org\/10.1038\/s41467-017-00530-7","DOI":"10.1038\/s41467-017-00530-7"},{"issue":"10","key":"10362_CR103","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020). The adenosine pathway in immuno-oncology. Nature Reviews. Clinical Oncology, 17(10), 611\u2013629. https:\/\/doi.org\/10.1038\/s41571-020-0382-2","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"1","key":"10362_CR104","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017). The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunological Reviews, 276(1), 121\u2013144. https:\/\/doi.org\/10.1111\/imr.12528","journal-title":"Immunological Reviews"},{"issue":"12","key":"10362_CR105","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41577-020-0376-4","volume":"20","author":"AK Moesta","year":"2020","unstructured":"Moesta, A. K., Li, X.-Y., & Smyth, M. J. (2020). Targeting CD39 in cancer. Nature Reviews. Immunology, 20(12), 739\u2013755. https:\/\/doi.org\/10.1038\/s41577-020-0376-4","journal-title":"Nature Reviews. Immunology"},{"issue":"9","key":"10362_CR106","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41416-024-02640-8","volume":"130","author":"Z Ning","year":"2024","unstructured":"Ning, Z., Liu, K., Zhang, H., Dong, G., Wang, X., & Xiong, H. (2024). Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis. British Journal of Cancer, 130(9), 1542\u20131551. https:\/\/doi.org\/10.1038\/s41416-024-02640-8","journal-title":"British Journal of Cancer"},{"key":"10362_CR107","doi-asserted-by":"publisher","unstructured":"Spillane, C. D., Cooke, N. M., Ward, M. P., Kenny, D., Blackshields, G., Kelly, T., \u2026 & O\u2019Leary, J. J. (2021). The induction of a mesenchymal phenotype by platelet cloaking of cancer cells is a universal phenomenon. Translational Oncology, 14(12), 101229. https:\/\/doi.org\/10.1016\/j.tranon.2021.101229","DOI":"10.1016\/j.tranon.2021.101229"},{"issue":"5","key":"10362_CR108","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41416-024-02797-2","volume":"131","author":"MP Ward","year":"2024","unstructured":"Ward, M. P., O\u2019Toole, S. A., & O\u2019Leary, J. J. (2024). Potential role of the CD39-CD73 ATP-adenosine pathway in platelet mediated dissemination of circulating tumour cells. British Journal of Cancer, 131(5), 781\u2013782. https:\/\/doi.org\/10.1038\/s41416-024-02797-2","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10362_CR109","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023). Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nature Reviews. Immunology, 23(2), 90\u2013105. https:\/\/doi.org\/10.1038\/s41577-022-00732-1","journal-title":"Nature Reviews. Immunology"},{"key":"10362_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018). Natural killer cells: Development, maturation, and clinical utilization. Frontiers in Immunology, 9, Article 1869. https:\/\/doi.org\/10.3389\/fimmu.2018.01869","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10362_CR111","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008). Functions of natural killer cells. Nature Immunology, 9(5), 503\u2013510. https:\/\/doi.org\/10.1038\/ni1582","journal-title":"Nature Immunology"},{"key":"10362_CR112","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fimmu.2018.00441","volume":"9","author":"FM Wensveen","year":"2018","unstructured":"Wensveen, F. M., Jelen\u010di\u0107, V., & Poli\u0107, B. (2018). NKG2D: A master regulator of immune cell responsiveness. Frontiers in Immunology, 9, 441. https:\/\/doi.org\/10.3389\/fimmu.2018.00441","journal-title":"Frontiers in Immunology"},{"issue":"6852","key":"10362_CR113","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/35093109","volume":"413","author":"A Diefenbach","year":"2001","unstructured":"Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001). Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature, 413(6852), 165\u2013171. https:\/\/doi.org\/10.1038\/35093109","journal-title":"Nature"},{"issue":"5","key":"10362_CR114","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1084\/jem.20050994","volume":"202","author":"MJ Smyth","year":"2005","unstructured":"Smyth, M. J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005). NKG2D function protects the host from tumor initiation. The Journal of Experimental Medicine, 202(5), 583\u2013588. https:\/\/doi.org\/10.1084\/jem.20050994","journal-title":"The Journal of Experimental Medicine"},{"issue":"3","key":"10362_CR115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211538","volume":"14","author":"CD Cluxton","year":"2019","unstructured":"Cluxton, C. D., Spillane, C., O\u2019Toole, S. A., Sheils, O., Gardiner, C. M., & O\u2019Leary, J. J. (2019). Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade. PLoS ONE, 14(3), Article e0211538. https:\/\/doi.org\/10.1371\/journal.pone.0211538","journal-title":"PLoS ONE"},{"key":"10362_CR116","doi-asserted-by":"publisher","unstructured":"Maurer, S., Kropp, K. N., Klein, G., Steinle, A., Haen, S. P., Walz, J. S., \u2026 & Salih, H. R. (2018). Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncoimmunology, 7(2), e1364827. https:\/\/doi.org\/10.1080\/2162402X.2017.1364827","DOI":"10.1080\/2162402X.2017.1364827"},{"issue":"3","key":"10362_CR117","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10585-010-9311-6","volume":"27","author":"T Wiesner","year":"2010","unstructured":"Wiesner, T., Bugl, S., Mayer, F., Hartmann, J. T., & Kopp, H.-G. (2010). Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clinical & Experimental Metastasis, 27(3), 141\u2013149. https:\/\/doi.org\/10.1007\/s10585-010-9311-6","journal-title":"Clinical & Experimental Metastasis"},{"issue":"3","key":"10362_CR118","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E., & Joyce, J. A. (2023). The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 41(3), 374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016","journal-title":"Cancer Cell"},{"issue":"16","key":"10362_CR119","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson, N. M., & Simon, M. C. (2020). The tumor microenvironment. Current Biology: CB, 30(16), R921\u2013R925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081","journal-title":"Current Biology: CB"},{"key":"10362_CR120","doi-asserted-by":"publisher","unstructured":"Liu, X., Song, J., Zhang, H., Liu, X., Zuo, F., Zhao, Y., \u2026 & Shi, H. (2023). Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell, 41(2), 272\u2013287.e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.001","DOI":"10.1016\/j.ccell.2023.01.001"},{"issue":"5","key":"10362_CR121","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1084\/jem.161.5.1063","volume":"161","author":"GF Burns","year":"1985","unstructured":"Burns, G. F., Triglia, T., Werkmeister, J. A., Begley, C. G., & Boyd, A. W. (1985). TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors. The Journal of Experimental Medicine, 161(5), 1063\u20131078. https:\/\/doi.org\/10.1084\/jem.161.5.1063","journal-title":"The Journal of Experimental Medicine"},{"issue":"5","key":"10362_CR122","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.semcancer.2006.07.002","volume":"16","author":"A Fuchs","year":"2006","unstructured":"Fuchs, A., & Colonna, M. (2006). The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Seminars in Cancer Biology, 16(5), 359\u2013366. https:\/\/doi.org\/10.1016\/j.semcancer.2006.07.002","journal-title":"Seminars in Cancer Biology"},{"key":"10362_CR123","doi-asserted-by":"publisher","unstructured":"Shibuya, A., Campbell, D., Hannum, C., Yssel, H., Franz-Bacon, K., McClanahan, T., \u2026 & Phillips, J. H. (1996). DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity, 4(6), 573\u2013581. https:\/\/doi.org\/10.1016\/s1074-7613(00)70060-4","DOI":"10.1016\/s1074-7613(00)70060-4"},{"key":"10362_CR124","doi-asserted-by":"publisher","unstructured":"Shibuya, K., Lanier, L. L., Phillips, J. H., Ochs, H. D., Shimizu, K., Nakayama, E., \u2026 & Shibuya, A. (1999). Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity, 11(5), 615\u2013623. https:\/\/doi.org\/10.1016\/s1074-7613(00)80136-3","DOI":"10.1016\/s1074-7613(00)80136-3"},{"key":"10362_CR125","doi-asserted-by":"crossref","unstructured":"Scott, J. L., Dunn, S. M., Jin, B., Hillam, A. J., Walton, S., Berndt, M. C., \u2026 & Burns, G. F. (1989). Characterization of a novel membrane glycoprotein involved in platelet activation. The Journal of Biological Chemistry, 264(23), 13475\u201313482.","DOI":"10.1016\/S0021-9258(18)80021-7"},{"key":"10362_CR126","doi-asserted-by":"publisher","unstructured":"Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., \u2026 & Moretta, A. (2003). Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. The Journal of Experimental Medicine, 198(4), 557\u2013567. https:\/\/doi.org\/10.1084\/jem.20030788","DOI":"10.1084\/jem.20030788"},{"key":"10362_CR127","doi-asserted-by":"publisher","unstructured":"Pende, D., Bottino, C., Castriconi, R., Cantoni, C., Marcenaro, S., Rivera, P., \u2026 Moretta, A. & (2005). PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Molecular Immunology, 42(4), 463\u2013469. https:\/\/doi.org\/10.1016\/j.molimm.2004.07.028","DOI":"10.1016\/j.molimm.2004.07.028"},{"issue":"7","key":"10362_CR128","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.4049\/jimmunol.172.7.3994","volume":"172","author":"A Fuchs","year":"2004","unstructured":"Fuchs, A., Cella, M., Giurisato, E., Shaw, A. S., & Colonna, M. (2004). Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). Journal of Immunology (Baltimore, Md.\u202f: 1950), 172(7), 3994\u20133998. https:\/\/doi.org\/10.4049\/jimmunol.172.7.3994","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"key":"10362_CR129","doi-asserted-by":"publisher","unstructured":"Chan, C. J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M. T., Town, L., \u2026 & Smyth, M. J. (2014). The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nature Immunology, 15(5), 431\u2013438. https:\/\/doi.org\/10.1038\/ni.2850","DOI":"10.1038\/ni.2850"},{"issue":"3","key":"10362_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/biology12030452","volume":"12","author":"D Hermans","year":"2023","unstructured":"Hermans, D., van Beers, L., & Broux, B. (2023). Nectin family ligands trigger immune effector functions in health and autoimmunity. Biology, 12(3), Article 452. https:\/\/doi.org\/10.3390\/biology12030452","journal-title":"Biology"},{"key":"10362_CR131","doi-asserted-by":"publisher","unstructured":"Meyer, D., Seth, S., Albrecht, J., Maier, M. K., du Pasquier, L., Ravens, I., \u2026 & Bernhardt, G. (2009). CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains. The Journal of Biological Chemistry, 284(4), 2235\u20132244. https:\/\/doi.org\/10.1074\/jbc.M807698200","DOI":"10.1074\/jbc.M807698200"},{"key":"10362_CR132","doi-asserted-by":"publisher","unstructured":"Sun, Y., Li, T., Ding, L., Wang, J., Chen, C., Liu, T., \u2026 & Guo, W. (2025). Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT. Hepatology (Baltimore, Md.), 81(3), 791\u2013807. https:\/\/doi.org\/10.1097\/HEP.0000000000000934","DOI":"10.1097\/HEP.0000000000000934"},{"key":"10362_CR133","doi-asserted-by":"publisher","unstructured":"Weimer, P., Wellbrock, J., Sturmheit, T., Oliveira-Ferrer, L., Ding, Y., Menzel, S., \u2026 & Brauneck, F. (2022). Tissue-specific expression of TIGIT, PD-1, TIM-3, and CD39 by \u03b3\u03b4 T cells in ovarian cancer. Cells, 11(6), 964. https:\/\/doi.org\/10.3390\/cells11060964","DOI":"10.3390\/cells11060964"},{"key":"10362_CR134","doi-asserted-by":"publisher","unstructured":"He, W., Zhang, H., Han, F., Chen, X., Lin, R., Wang, W., \u2026 & Ke, Z. (2017). CD155T\/TIGIT Signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Research, 77(22), 6375\u20136388. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0381","DOI":"10.1158\/0008-5472.CAN-17-0381"},{"issue":"1","key":"10362_CR135","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang, P., Liu, X., Gu, Z., Jiang, Z., Zhao, S., Song, Y., & Yu, J. (2024). Targeting TIGIT for cancer immunotherapy: Recent advances and future directions. Biomarker Research, 12(1), 7. https:\/\/doi.org\/10.1186\/s40364-023-00543-z","journal-title":"Biomarker Research"},{"issue":"2","key":"10362_CR136","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"J-M Chauvin","year":"2020","unstructured":"Chauvin, J.-M., & Zarour, H. M. (2020). TIGIT in cancer immunotherapy. Journal for Immunotherapy of Cancer, 8(2), Article e000957. https:\/\/doi.org\/10.1136\/jitc-2020-000957","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"10362_CR137","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4049\/jimmunol.1103194","volume":"189","author":"T Placke","year":"2012","unstructured":"Placke, T., Salih, H. R., & Kopp, H.-G. (2012). GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. Journal of Immunology (Baltimore, Md.\u202f: 1950), 189(1), 154\u2013160. https:\/\/doi.org\/10.4049\/jimmunol.1103194","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"key":"10362_CR138","doi-asserted-by":"publisher","unstructured":"Gurney, A. L., Marsters, S. A., Huang, R. M., Pitti, R. M., Mark, D. T., Baldwin, D. T., \u2026 & Ashkenazi, A. (1999). Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Current biology: CB, 9(4), 215\u2013218. https:\/\/doi.org\/10.1016\/s0960-9822(99)80093-1","DOI":"10.1016\/s0960-9822(99)80093-1"},{"key":"10362_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588682","volume":"11","author":"J Tian","year":"2020","unstructured":"Tian, J., Zhang, B., Rui, K., & Wang, S. (2020). The role of GITR\/GITRL interaction in autoimmune diseases. Frontiers in Immunology, 11, Article 588682. https:\/\/doi.org\/10.3389\/fimmu.2020.588682","journal-title":"Frontiers in Immunology"},{"key":"10362_CR140","doi-asserted-by":"publisher","unstructured":"Baltz, K. M., Krusch, M., Bringmann, A., Brossart, P., Mayer, F., Kloss, M., \u2026 & Salih, H. R. (2007). Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell\/tumor cell interactions. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 21(10), 2442\u20132454. https:\/\/doi.org\/10.1096\/fj.06-7724com","DOI":"10.1096\/fj.06-7724com"},{"key":"10362_CR141","doi-asserted-by":"publisher","unstructured":"Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., \u2026 Sakaguchi, S. (2005). Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. The Journal of Experimental Medicine, 202(7), 885\u2013891. https:\/\/doi.org\/10.1084\/jem.20050940","DOI":"10.1084\/jem.20050940"},{"key":"10362_CR142","doi-asserted-by":"publisher","unstructured":"Zhou, Y., Heitmann, J. S., Clar, K. L., Kropp, K. N., Hinterleitner, M., Engler, T., \u2026 & Hinterleitner, C. (2021). Platelet-expressed immune checkpoint regulator GITRL in breast cancer. Cancer Immunology, Immunotherapy: CII, 70(9), 2483\u20132496. https:\/\/doi.org\/10.1007\/s00262-021-02866-y","DOI":"10.1007\/s00262-021-02866-y"},{"issue":"4","key":"10362_CR143","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4172\/2332-0877.1000149","volume":"2","author":"Y Ferrer-Acosta","year":"2014","unstructured":"Ferrer-Acosta, Y., Gonz\u00e1lez, M., Fern\u00e1ndez, M., & Valance, W. A. (2014). Emerging roles for platelets in inflammation and disease. Journal of Infectious Disease and Therapy, 2(4), 149. https:\/\/doi.org\/10.4172\/2332-0877.1000149","journal-title":"Journal of Infectious Disease and Therapy"},{"key":"10362_CR144","doi-asserted-by":"publisher","unstructured":"Barrow, A. D., Astoul, E., Floto, A., Brooke, G., Relou, I. A. M., Jennings, N. S., \u2026 & Trowsdale, J. (2004). Cutting edge: TREM-like transcript-1, a platelet immunoreceptor tyrosine-based inhibition motif encoding costimulatory immunoreceptor that enhances, rather than inhibits, calcium signaling via SHP-2. Journal of Immunology (Baltimore, Md.: 1950), 172(10), 5838\u20135842. https:\/\/doi.org\/10.4049\/jimmunol.172.10.5838","DOI":"10.4049\/jimmunol.172.10.5838"},{"issue":"4","key":"10362_CR145","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/blood-2004-01-0315","volume":"104","author":"AV Washington","year":"2004","unstructured":"Washington, A. V., Schubert, R. L., Quigley, L., Disipio, T., Feltz, R., Cho, E. H., & McVicar, D. W. (2004). A TREM family member, TLT-1, is found exclusively in the alpha-granules of megakaryocytes and platelets. Blood, 104(4), 1042\u20131047. https:\/\/doi.org\/10.1182\/blood-2004-01-0315","journal-title":"Blood"},{"issue":"19","key":"10362_CR146","doi-asserted-by":"publisher","first-page":"13396","DOI":"10.1074\/jbc.M600489200","volume":"281","author":"JL Gattis","year":"2006","unstructured":"Gattis, J. L., Washington, A. V., Chisholm, M. M., Quigley, L., Szyk, A., McVicar, D. W., & Lubkowski, J. (2006). The structure of the extracellular domain of triggering receptor expressed on myeloid cells like transcript-1 and evidence for a naturally occurring soluble fragment. Journal of Biological Chemistry, 281(19), 13396\u201313403. https:\/\/doi.org\/10.1074\/jbc.M600489200","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"10362_CR147","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1160\/TH06-08-0456","volume":"97","author":"B Giomarelli","year":"2007","unstructured":"Giomarelli, B., Washington, V. A., Chisholm, M. M., Quigley, L., McMahon, J. B., Mori, T., & McVicar, D. W. (2007). Inhibition of thrombin-induced platelet aggregation using human single-chain Fv antibodies specific for TREM-like transcript-1. Thrombosis and Haemostasis, 97(6), 955\u2013963.","journal-title":"Thrombosis and Haemostasis"},{"key":"10362_CR148","doi-asserted-by":"publisher","unstructured":"Washington, A. V., Gibot, S., Acevedo, I., Gattis, J., Quigley, L., Feltz, R., \u2026 & McVicar, D. W. (2009). TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. The Journal of Clinical Investigation, 119(6), 1489\u20131501. https:\/\/doi.org\/10.1172\/JCI36175","DOI":"10.1172\/JCI36175"},{"issue":"6","key":"10362_CR149","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/09537104.2021.1881948","volume":"32","author":"S Branfield","year":"2021","unstructured":"Branfield, S., & Washington, A. V. (2021). The enigmatic nature of the triggering receptor expressed in myeloid cells -1 (TLT- 1). Platelets, 32(6), 753\u2013760. https:\/\/doi.org\/10.1080\/09537104.2021.1881948","journal-title":"Platelets"},{"key":"10362_CR150","doi-asserted-by":"publisher","unstructured":"Morales-Ort\u00edz, J., Deal, V., Reyes, F., Maldonado-Mart\u00ednez, G., Ledesma, N., Staback, F., \u2026 & Washington, A. V. (2018). Platelet-derived TLT-1 is a prognostic indicator in ALI\/ARDS and prevents tissue damage in the lungs in a mouse model. Blood, 132(23), 2495\u20132505. https:\/\/doi.org\/10.1182\/blood-2018-03-841593","DOI":"10.1182\/blood-2018-03-841593"},{"key":"10362_CR151","doi-asserted-by":"publisher","unstructured":"Tyagi, T., Jain, K., Yarovinsky, T. O., Chiorazzi, M., Du, J., Castro, C., \u2026 & Hwa, J. (2023). Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. The Journal of Experimental Medicine, 220(1), e20212218. https:\/\/doi.org\/10.1084\/jem.20212218","DOI":"10.1084\/jem.20212218"},{"key":"10362_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.631285","volume":"12","author":"A Saris","year":"2021","unstructured":"Saris, A., Steuten, J., Schrijver, D. P., van Schijndel, G., Zwaginga, J. J., van Ham, S. M., & Ten Brinke, A. (2021). Inhibition of dendritic cell activation and modulation of T cell polarization by the platelet secretome. Frontiers in Immunology, 12, Article 631285. https:\/\/doi.org\/10.3389\/fimmu.2021.631285","journal-title":"Frontiers in Immunology"},{"key":"10362_CR153","doi-asserted-by":"publisher","unstructured":"Kuratani, A., Okamoto, M., Kishida, K., Okuzaki, D., Sasai, M., Sakaguchi, S., \u2026 & Yamamoto, M. (2024). Platelet factor 4-induced TH1-Treg polarization suppresses antitumor immunity. Science (New York, N.Y.), 386(6724), eadn8608. https:\/\/doi.org\/10.1126\/science.adn8608","DOI":"10.1126\/science.adn8608"},{"key":"10362_CR154","doi-asserted-by":"publisher","unstructured":"Wang, L., Wang, H., Zhu, M., Ni, X., Sun, L., Wang, W., \u2026 & Hou, Y. (2024). Platelet-derived TGF-\u03b21 induces functional reprogramming of myeloid-derived suppressor cells in\u00a0immune thrombocytopenia. Blood, 144(1), 99\u2013112. https:\/\/doi.org\/10.1182\/blood.2023022738","DOI":"10.1182\/blood.2023022738"},{"issue":"20","key":"10362_CR155","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1182\/blood-2008-10-186585","volume":"114","author":"H L\u00e4ubli","year":"2009","unstructured":"L\u00e4ubli, H., Spanaus, K.-S., & Borsig, L. (2009). Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood, 114(20), 4583\u20134591. https:\/\/doi.org\/10.1182\/blood-2008-10-186585","journal-title":"Blood"},{"key":"10362_CR156","doi-asserted-by":"publisher","unstructured":"Muhuitijiang, B., Zhou, J., Zhou, R., Zhang, Z., Yan, G., Zheng, Z., \u2026 & Tan, W. (2024). Development and experimental validation of an M2 macrophage and platelet-associated gene signature to predict prognosis and immunotherapy sensitivity in bladder cancer. Cancer Science, 115(5), 1417\u20131432. https:\/\/doi.org\/10.1111\/cas.16113","DOI":"10.1111\/cas.16113"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10362-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10362-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10362-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:37:56Z","timestamp":1785897476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10362-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":156,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["10362"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10362-x","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"55"}}